262 related articles for article (PubMed ID: 9642078)
1. Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands.
Rahuel J; García-Echeverría C; Furet P; Strauss A; Caravatti G; Fretz H; Schoepfer J; Gay B
J Mol Biol; 1998 Jun; 279(4):1013-22. PubMed ID: 9642078
[TBL] [Abstract][Full Text] [Related]
2. Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor.
Nioche P; Liu WQ; Broutin I; Charbonnier F; Latreille MT; Vidal M; Roques B; Garbay C; Ducruix A
J Mol Biol; 2002 Feb; 315(5):1167-77. PubMed ID: 11827484
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domain.
Furet P; Gay B; García-Echeverría C; Rahuel J; Fretz H; Schoepfer J; Caravatti G
J Med Chem; 1997 Oct; 40(22):3551-6. PubMed ID: 9357522
[TBL] [Abstract][Full Text] [Related]
4. Solution structure of the SH2 domain of Grb2 complexed with the Shc-derived phosphotyrosine-containing peptide.
Ogura K; Tsuchiya S; Terasawa H; Yuzawa S; Hatanaka H; Mandiyan V; Schlessinger J; Inagaki F
J Mol Biol; 1999 Jun; 289(3):439-45. PubMed ID: 10356320
[TBL] [Abstract][Full Text] [Related]
5. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck.
Eck MJ; Shoelson SE; Harrison SC
Nature; 1993 Mar; 362(6415):87-91. PubMed ID: 7680435
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain.
Furet P; Gay B; Caravatti G; García-Echeverría C; Rahuel J; Schoepfer J; Fretz H
J Med Chem; 1998 Aug; 41(18):3442-9. PubMed ID: 9719597
[TBL] [Abstract][Full Text] [Related]
7. Dual specificity of Src homology 2 domains for phosphotyrosine peptide ligands.
Gay B; Furet P; García-Echeverría C; Rahuel J; Chène P; Fretz H; Schoepfer J; Caravatti G
Biochemistry; 1997 May; 36(19):5712-8. PubMed ID: 9153411
[TBL] [Abstract][Full Text] [Related]
8. Thermodynamic and structural analysis of phosphotyrosine polypeptide binding to Grb2-SH2.
McNemar C; Snow ME; Windsor WT; Prongay A; Mui P; Zhang R; Durkin J; Le HV; Weber PC
Biochemistry; 1997 Aug; 36(33):10006-14. PubMed ID: 9254595
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of conformationally constrained Grb2 SH2 domain binding peptides employing alpha-methylphenylalanyl based phosphotyrosyl mimetics.
Oishi S; Karki RG; Kang SU; Wang X; Worthy KM; Bindu LK; Nicklaus MC; Fisher RJ; Burke TR
J Med Chem; 2005 Feb; 48(3):764-72. PubMed ID: 15689160
[TBL] [Abstract][Full Text] [Related]
10. Solution structure of the C-terminal SH2 domain of the p85 alpha regulatory subunit of phosphoinositide 3-kinase.
Siegal G; Davis B; Kristensen SM; Sankar A; Linacre J; Stein RC; Panayotou G; Waterfield MD; Driscoll PC
J Mol Biol; 1998 Feb; 276(2):461-78. PubMed ID: 9512716
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of small phosphopeptides, inhibitors of Grb2 SH2 domain, and their prodrugs.
Liu WQ; Vidal M; Olszowy C; Million E; Lenoir C; Dhôtel H; Garbay C
J Med Chem; 2004 Feb; 47(5):1223-33. PubMed ID: 14971902
[TBL] [Abstract][Full Text] [Related]
12. Solution structure and dynamics of G1TE, a nonphosphorylated cyclic peptide inhibitor for the Grb2 SH2 domain.
Lou YC; Lung FD; Pai MT; Tzeng SR; Wei SY; Roller PP; Cheng JW
Arch Biochem Biophys; 1999 Dec; 372(2):309-14. PubMed ID: 10600169
[TBL] [Abstract][Full Text] [Related]
13. Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1).
Ettmayer P; France D; Gounarides J; Jarosinski M; Martin MS; Rondeau JM; Sabio M; Topiol S; Weidmann B; Zurini M; Bair KW
J Med Chem; 1999 Mar; 42(6):971-80. PubMed ID: 10090780
[TBL] [Abstract][Full Text] [Related]
14. Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems.
Wei CQ; Gao Y; Lee K; Guo R; Li B; Zhang M; Yang D; Burke TR
J Med Chem; 2003 Jan; 46(2):244-54. PubMed ID: 12519063
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands.
Yao ZJ; King CR; Cao T; Kelley J; Milne GW; Voigt JH; Burke TR
J Med Chem; 1999 Jan; 42(1):25-35. PubMed ID: 9888830
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of peptide molecular recognition by phospholipase C gamma-1 Src homology-2 domain and a mutant Tyr phosphatase PTP1bC215S.
MacLean D; Sefler AM; Zhu G; Decker SJ; Saltiel AR; Singh J; McNamara D; Dobrusin EM; Sawyer TK
Protein Sci; 1995 Jan; 4(1):13-20. PubMed ID: 7773170
[TBL] [Abstract][Full Text] [Related]
17. Binding affinity difference induced by the stereochemistry of the sulfoxide bridge of the cyclic peptide inhibitors of Grb2-SH2 domain: NMR studies for the structural origin.
Shi YH; Song YL; Lin DH; Tan J; Roller PP; Li Q; Long YQ; Song GQ
Biochem Biophys Res Commun; 2005 May; 330(4):1254-61. PubMed ID: 15823578
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of rosmarinic acid on Lck SH2 domain binding to a synthetic phosphopeptide.
Ahn SC; Oh WK; Kim BY; Kang DO; Kim MS; Heo GY; Ahn JS
Planta Med; 2003 Jul; 69(7):642-6. PubMed ID: 12898421
[TBL] [Abstract][Full Text] [Related]
19. Grb2 SH2 domain-binding peptide analogs as potential anticancer agents.
Lung FD; Tsai JY
Biopolymers; 2003; 71(2):132-40. PubMed ID: 12767115
[TBL] [Abstract][Full Text] [Related]
20. Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution.
Tong L; Warren TC; King J; Betageri R; Rose J; Jakes S
J Mol Biol; 1996 Mar; 256(3):601-10. PubMed ID: 8604142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
